U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. SaveWay Compounding Pharmacy, Inc. - 03/28/2018
  1. Warning Letters

CLOSEOUT LETTER

SaveWay Compounding Pharmacy, Inc.


Recipient:
SaveWay Compounding Pharmacy, Inc.

United States

Issuing Office:

United States


 

  

Black HHS-Blue FDA Logo

 

 

 
Division of Pharmaceutical Quality Operations I
10 Waterview Blvd, 3rd FL
Parsippany, NJ 07054
Telephone: (973) 331-4900
FAX: (973) 331-4969

March 28, 2018

Brenda L. Poland Vice President
SaveWay Compounding Pharmacy, Inc.
31 Albe Drive, Suite 1
Newark, DE 19702-1360

Dear Ms. Poland:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (WL #17-PHI-01) dated October 4, 2016. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Yvette Johnson, Compliance Officer
Office of Pharmaceutical Quality Operations, Division I
Philadelphia District Office 

Back to Top